Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, N. K.
Right arrow Articles by Choi, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, N. K.
Right arrow Articles by Choi, K. G.
Related Collections
Right arrow Stroke prevention
Right arrow All Cerebrovascular disease/Stroke
Right arrow Risk factors in epidemiology
Right arrow Infarction
NEUROLOGY 2003;61:1595-1599
© 2003 American Academy of Neurology

Hyperhomocysteinemia as an independent risk factor for silent brain infarction

N. K. Kim, PhD, B. O. Choi, MD PhD, W. S. Jung, MD PhD, Y. J. Choi, MD and K. G. Choi, MD PhD

From the Department of Neurology and Ewha Medical Research Center (Drs. B.O. Choi, Y.J. Choi, and K.G. Choi), College of Medicine, Ewha Womans University, Seoul; Institute for Clinical Research (Dr. Kim), College of Medicine, Pochon CHA University, Sungnam; and Stroke Center (Dr. Jung), College of Oriental Medicine, Kyung Hee University, Seoul, South Korea.

Address correspondence and reprint requests to Dr. Byung-Ok Choi, Department of Neurology, Ewha Womans University, Dongdaemun Hospital, 70, Jongro 6-ga, Jongro-gu, Seoul, 110-783, South Korea; e-mail: bochoi{at}ewha.ac.kr

Objective: To evaluate whether hyperhomocysteinemia is an independent risk factor for silent brain infarction (SBI), and to determine the relationship between homocysteine and folate in each type of methylenetetrahydrofolate reductase (MTHFR) polymorphism, in order to identify a way of reducing the risk for SBI.

Methods: The authors enrolled 161 patients with SBI and 126 healthy people, checked their fasting homocysteine and folate levels, and analyzed for the MTHFR C677T polymorphism.

Results: The mean plasma homocysteine level in patients with SBI (12.17 ± 5.35 µmol/L) was significantly higher than in normal healthy people (9.37 ± 4.11 µmol/L; p < 0.05). By subgroup analysis, based on the classification of plasma homocysteine levels as high (>=11.77 µmol/L), moderate (8.71 to 11.76 µmol/L), and low (<=8.70 µmol/L), the adjusted OR (AOR) of the high group for SBI was significantly greater than that of the low group (AOR, 4.78; 95% CI, 2.45 to 9.33). The homocysteine level showed a significant inverse correlation with folate level only in patients with SBI with the MTHFR 677TT genotype (p < 0.05).

Conclusions: This study demonstrates that hyperhomocysteinemia is an independent risk factor for SBI, and provides the possibility of reducing the risk for SBI in the MTHFR 677TT genotype by folate supplementation.

Received May 2, 2003. Accepted in final form August 13, 2003.




This article has been cited by other articles:


Home page
 StrokeHome page
T. Hoshi, K. Kitagawa, H. Yamagami, S. Furukado, H. Hougaku, and M. Hori
Relations of Serum High-Sensitivity C-Reactive Protein and Interleukin-6 Levels With Silent Brain Infarction
Stroke, April 1, 2005; 36(4): 768 - 772.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.